Active Ingredient History

NOW
  • Now
Beclabuvir is an antiviral drug for the treatment of hepatitis C virus (HCV) infection that has been studied in clinical trials. In February 2017, Bristol-Myers Squibb began sponsoring a post-marketing trial of beclabuvir, in combination with asunaprevir and daclatasvir, to study the combination's safety profile with regard to liver function. From February 2014 to November 2016, a phase II clinical trial was conducted on the combination of asunaprevir/daclatasvir/beclabuvir on patients infected with both HIV and HCV. Furthermore, a recent meta-analysis of six published six clinical trials showed high response rates in HCV genotype 1-infected patients treated with daclatasvir, asunaprevir, and beclabuvir irrespective of ribavirin use, prior interferon-based therapy, or restriction on noncirrhotic patients, IL28B genotype, or baseline resistance-associated variants   Wikipedia

  • SMILES: COc1ccc2c(c1)[C@@H]3C[C@@]3(Cn4c2c(C5CCCCC5)c6ccc(cc46)C(=O)NS(=O)(=O)N(C)C)C(=O)N7C8CCC7CN(C)C8
  • InChIKey: ZTTKEBYSXUCBSE-VSBZUFFNSA-N
  • Mol. Mass: 659.85
  • ALogP: 4.69
  • ChEMBL Molecule:
More Chemistry
8-cyclohexyl-n-((dimethylamino)sulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)cycloprop(d)indolo(2,1-a)(2)benzazepine-5-carboxamide | beclabuvir | bms-791325

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue